None listed
Conditions
Brief summary
The patients from which this data will be drawn were referred to the clinic by their general practitioner with symptomatic joint osteoarthritis for whom injection of hyaluronic acid (Durolane) was found to be the most appropriate treatment. This data is collected on all patients undergoing such injections as a routine pre and post injection measures of their pain and function. For those who had more than one injection, the time in days between injections will be analysed. Patient data will be included in the analyses if they were >18 years old with painful hip osteoarthritis and mild to moderate radiological changes on their imaging. There was no maximum age limit applied to the inclusion criteria. There were no specific inclusion or exclusion criteria in regards to race and gender. The current data set of the patient cohort intended for analysis was collected over 4 years.The data from these patients who have recieved Durolane injections in normal clinical practice will be analysed retrospectively.
Interventions
Data was obtained from patients who had treatment between January 2016 and December 2017 from patients who had received a single injection of hyaluronic acid (HA) (Durolane; and from patients who had had two or more injections up to December 2019. 3ml preparation) in accordance with the manufacturer’s guidelines as a part of their treatment with their surgeon or sports physician. This was performed according to standard hip injection technique with the patient supine using aseptic technique unde
Data was obtained from patients who had treatment between January 2016 and December 2017 from patients who had received a single injection of hyaluronic acid (HA) (Durolane; and from patients who had had two or more injections up to December 2019. 3ml preparation) in accordance with the manufacturer’s guidelines as a part of their treatment with their surgeon or sports physician. This was performed according to standard hip injection technique with the patient supine using aseptic technique under ultrasound guidance. A sterile 21 g spinal needle was used with infiltration of 2-3 mls of lignocaine 2% (Xylocaine, Astra Zeneca, UK) sub-cuticularly and on the hip capsule. Durolane 3mls was then injected intra-articularly.
Sponsors
Joint Health Institute
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients who have had one or more Durolane injections for osteoarthritis between January 2016 and December 2019
Exclusion criteria
1. Patients presenting with severe (Kellgren-Lawrence grade 4) OA, 2. inflammatory arthropathy 3. avascular necrosis.
Outcome results
None listed